Role of Atosiban in Recurrent Implantation Failure (RIF)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04118959|
Recruitment Status : Recruiting
First Posted : October 8, 2019
Last Update Posted : November 20, 2019
|Condition or disease|
|Recurrent Implantation Failure|
ET is a critical step of an IVF cycle that merits the utmost attention. Its success depends on the frequency of uterine contractions, the endometrial receptivity and the quality of embryos transferred.
Uterine contractions are the most fundamental constituents of the uterine receptivity. Excessive contractions may decrease the implantation potential of embryos by expelling the embryos from the uterus. Studies have revealed a six-fold increase in uterine contractility in IVF cycles when measured before ET as compared to the condition before ovulation in natural cycles. Excessive manipulation of the cervix such as the use of tenaculum during difficult ET can also trigger uterine contractions, consequently leading to failure of embryo implantation.
IVF success rates have been potentially improved by the use of drugs that inhibit pronounced uterine contractions at the time of ET. Treatment strategies such as the use of beta-agonists or nonsteroidal anti-inflammatory agents for tocolysis have not been beneficial in IVF-ET procedures.
Atosiban is a combined oxytocin/vasopressin V1A antagonist. It functions mainly by blocking oxytocin and vasopressin V1a receptors to decrease the frequency and amplitude of uterine contractions, which enhances implantation and pregnancy rates. RIF remains unexplained in most cases, which results in considerable variation in how RIF is treated and managed. Atosiban competes with oxytocin at oxytocin receptors in endometrial cells and inhibits oxytocin-induced PGF2α release, thus inhibiting uterine contractions and increasing chances of embryo implantation and may add value in improving the outcome in RIF patients.
Recently published studies showed that atosiban inhibits oxytocin-induced PGF2α and uterine contractility, consequently leading to improved IRs. Studies have shown a considerable reduction in the frequency of uterine contractions before and after the administration of atosiban in women undergoing ET.
|Study Type :||Observational|
|Estimated Enrollment :||150 participants|
|Official Title:||The Value of Atosiban on the Day of Embryo Transfer in Patients With Recurrent Implantation Failure|
|Actual Study Start Date :||October 10, 2019|
|Estimated Primary Completion Date :||December 15, 2019|
|Estimated Study Completion Date :||December 15, 2019|
- pregnancy rate [ Time Frame: 2 weeks ]B- HCG
- clinical pregnancy rate [ Time Frame: 4 weeks ]positive fetal heart beats
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04118959
|Contact: Kamal eldin Rageh, M.D.||firstname.lastname@example.org|
|Contact: Ahmed Barakat, FRCOGemail@example.com|